Navigation Links
Report answers questions about E. coli: The good, the bad and the deadly
Date:11/15/2011

It has been the cause of infamous international foodborne disease outbreaks and yet it is the most studied bacterium in science, an essential part of the human digestive tract, and a backbone of the biotech industry. To enhance public understanding of the bacterium Escherichia coli, the American Academy of Microbiology brought together the nation's leading experts to consider and answer some of the most frequently asked questions about this multifaceted microorganism.

"The story of E. coli, what we are trying to tell in this report, is really much larger than just its role as a pathogen. It's been such a large component of research for so long so much of what we know about biology has come from studying E. coli," says Michael Doyle of the University of Georgia Center for Food Safety, a member of the steering committee.

The report, entitled FAQ E.coli: Good, Bad and Deadly is based on the deliberations of 13 of the nation's leading experts who met for one day in September 2011 to develop clear answers to frequently asked questions regarding the role of E. coli in scientific research, human health and foodborne disease.

Some of the questions considered by the report are:

  • What is E. coli anyway?
  • How has E. coli contributed to our understanding of biology?
  • What does naturally occurring E. coli in our GI tract do?
  • What is the difference between "good" E. coli that inhabits our GI tract and the "bad" E. coli that makes us sick?
  • Why does E. coli make some people sick and not others?
  • How does E. coli become pathogenic?
  • How does our food become contaminated with E. coli?
  • What steps are being taken to protect our food from contamination by pathogenic E. coli?
  • What types of food are most commonly associated with E. coli, and why do there seem to be more cases of contamination recently?

Most answers begin with a simple paragraph summarizing what is known, followed by a more detailed explanation. In addition, spread throughout the report are sidebar boxes discussing issues related to the questions such as a list of Nobel Prizes awarded for work done on E. coli and a discussion of toxins created by the bacterium.

FAQ E. coli: Good, Bad and Deadly is the latest offering in a series of reports designed to provide a rapid response to emerging issues. Traditionally Academy reports are based on multi-day colloquia after which the final report can take up to a year to develop. The FAQ series are based on single-day meetings focused on specific questions after which a final report is published in 2-3 months.

"The Academy FAQ reports explain complex microbiological problems in a timely, balanced format that is easily understandable by the public, the media and policy makers," says Stanley Maloy of San Diego State University, who moderated the colloquium.


'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

Related biology news :

1. New report offers broad approach to assessing impacts of ecological damage
2. Report provides new analysis of carbon accounting, biomass use, and climate benefits
3. BGI reports pig parasites genomic sequence provides new clues for parasitic diseases research
4. Aware, Inc. Reports Third Quarter 2011 Financial Results
5. Extreme melting on Greenland ice sheet, reports CCNY team
6. Scientists report major advance in human antibody therapy against deadly Hendra virus
7. Notre Dame researchers report progress on compound to treat neurological diseases
8. Study reports predictors of poor hand hygiene in an emergency department
9. Report showcases success of integrated development approaches
10. Reports highlight the evolving role of clinical microbiology laboratories
11. Researchers report new understanding of role of telomeres in tumor growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)... MINNETONKA, Minn. , Jan. 20, 2016   ... that supports the entire spectrum of clinical research, is ... in 2015. MedNet,s significant achievements are the result of ... of) iMedNet eClinical , it,s comprehensive, ... --> --> Key MedNet growth ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , ... a developer of innovative sensor-based diagnostic products, today announced the ... by new and existing investors.  Proceeds from the financing will ... Scanner , a hand-held device for detecting early-stage pressure ulcers. ... Ireland after receiving CE Mark approval. The ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Investor Conference 2016, to be held February 8-9, 2016, ... Group,s 2016 Disruptive Growth & Healthcare Conference, taking place ... 10-11, 2016. James Sapirstein , Chief Executive ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)... 3, 2016  With the growing need for ... is underway, therapies such as monoclonal antibodies, recombinant ... host of indications are in high demand. Conventionally ... development and production of these therapeutics. However, due ... high costs, novel approaches and novel expression systems ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier of ... North American healthcare market. , Aerocom Healthcare, LLC will be based in Denver, ... provide new pneumatic tube systems or expand existing systems within the U.S. and ...
Breaking Biology Technology: